293 related articles for article (PubMed ID: 15074169)
1. Illegal importation of pharmaceuticals: implications for community pharmacy and public health.
Fuller C
Manag Care; 2004 Mar; 13(3 Suppl):34-5. PubMed ID: 15074169
[No Abstract] [Full Text] [Related]
2. Where does drug importation stand now?
Guglielmo WJ
Med Econ; 2005 Mar; 82(6):42, 44, 46. PubMed ID: 15869085
[No Abstract] [Full Text] [Related]
3. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
Buckely M
Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
[No Abstract] [Full Text] [Related]
4. Seizures of Canadian drugs rise as Congress, Customs spar.
Carreyrou J
Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
[No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
Health Policy Tracking Service, A Service of Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
[No Abstract] [Full Text] [Related]
6. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: business practices.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-35. PubMed ID: 22423396
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals: drug importation.
Seay M; Jones TM
Issue Brief Health Policy Track Serv; 2007 Jan; ():1-15. PubMed ID: 17361466
[No Abstract] [Full Text] [Related]
9. Pharmaceuticals and medical devices: cost savings.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
[No Abstract] [Full Text] [Related]
10. Pharmaceuticals: drug importation--2005. End of Year Issue Brief.
Varma P; Seay M
Issue Brief Health Policy Track Serv; 2005 Dec; ():1-20. PubMed ID: 16708457
[No Abstract] [Full Text] [Related]
11. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
12. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference.
Enzi MB
Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090
[No Abstract] [Full Text] [Related]
13. Australian drugs scheme threatens free-trade talks.
Fickling D
Lancet; 2004 Jan; 363(9405):299. PubMed ID: 14753208
[No Abstract] [Full Text] [Related]
14. FDA chief attacks Canada's drug price controls.
Webster P
Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
[No Abstract] [Full Text] [Related]
15. Economic and policy implications of reimportation: a Canadian perspective.
Ward C
Manag Care; 2004 Mar; 13(3 Suppl):17-20. PubMed ID: 15074165
[No Abstract] [Full Text] [Related]
16. Legal implications of hospital resales of pharmaceuticals. American Hospital Association Office of General Counsel.
Am J Hosp Pharm; 1986 Aug; 43(8):1951-7. PubMed ID: 3752135
[TBL] [Abstract][Full Text] [Related]
17. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
Childs DW
Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
[No Abstract] [Full Text] [Related]
18. US drug importation plan hits snag.
Jaffe S
Lancet; 2021 Jun; 397(10291):2240. PubMed ID: 34119053
[No Abstract] [Full Text] [Related]
19. Vulnerable points in the U.S. drug-distribution system.
Shepherd M
Manag Care; 2004 Mar; 13(3 Suppl):25-9. PubMed ID: 15074167
[No Abstract] [Full Text] [Related]
20. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
Werling K; Abraham S; Strelec J
Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
